News
5h
TipRanks on MSNRegeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game-Changer for Chronic Rhinosinusitis TreatmentRegeneron Pharmaceuticals and Sanofi are conducting a Phase 3 clinical study titled A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Invest ...
Patients with atopic dermatitis experienced improvements in severity with 16 weeks of tralokinumab despite the number of ...
The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and ...
11h
Pharmaceutical Technology on MSNHealth Canada extends Evkeeza approval for children with HoFHThe decision follows the initial approval granted in September 2023, which covered patients aged five years and above.
Oversea Chinese Banking Corp Ltd acquired a $30.17 million stake in Regeneron Pharmaceuticals during the first quarter, ...
CT is your last chance to file a claim with 23andMe for a 2023 data breach that may have compromised your genetic data.
This LSPN panel features experts from Maiwald, Regeneron, Vertex Pharmaceuticals, and Taylor Wessing discussing the impact of ...
Morgan Stanley slightly lowered its price target for Regeneron Pharmaceuticals while maintaining an overweight rating, ...
This was the stock's fourth consecutive day of gains.
The trove of more than 200 letters is part of a pledge of transparency from the agency, with the intention to increase public ...
RFK Jr. cancels U.S. Preventive Services Task Force meeting; the Department of Health and Human Services backtracked on its claim that it would release ethics forms for new members of the Advisory ...
On the other side, on July 7, JP Morgan analyst Chris Schott reiterated a Buy rating on Regeneron, while maintaining his $800 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results